The global cervical cancer drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The growth of the market for these drugs is majorly attributed to the growing prevalence of cervical cancer. Adding to this, human papillomavirus (HPV) is a major causative factor for cervical cancer, which is usually acquired through sexual transmission; this factor too is anticipated to drive the market for cervical cancer drugs. There are more than 100 strains of HPV, out of which 13 are high risk or cancerous. Cervical cancer has a high mortality rate which can be reduced by diagnosis and prevention. Therefore, substantial government initiatives, coupled with the launch of targeted therapies are the major factors that will create awareness and thus the early diagnosis for cervical cancer among the global population. 

As the disease growth is usually slow, precancerous changes provide possibilities for prevention and treatment. Although most cases are diagnosed at almost last stages of disease growth due to the lack of awareness or inaccessibility to diagnostic facilities. Thus, the challenge of early diagnosis needs to be addressed so as to reduce the global healthcare burden of the disease. Further, regulatory approval for the various treatment drugs is also likely to spur the market growth. For instance, Avastin (bevacizumab) was approved for the treatment of cervical cancer in 2014. This marked the arrival of biologics in this treatment landscape. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. Following this, the FDA approved Keytruda (pembrolizumab) in 2018. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Cancer Type

o By Product Type

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  Pfizer Inc., F. Hoffman La-Roche AG, and GlaxoSmithKline plc, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Cervical Cancer Drugs Market Report by Segment

By Cancer Type

    • Squamous Cell Cancer

    • Adenocarcinoma

By Product Type

• Prevention

o Cervarix

o Gardasil 9

o Recombinant Human Papillomavirus (HPV) Bivalent Vaccine

o Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine

o Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine

o Others

• Treatment

o Avastin

o Bevacizumab

o Bleomycin

o Blenoxane

o Others

Global Cervical Cancer Drugs Market by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa